Biomarkers in Drug Discovery - Earlier Usage of Biomarkers in Optimization Stage to Reduce Drug Attrition Rate Significantly
- Published: October 2011
The Biomarker Partnering Yearbook 2013 report series provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2012.
Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide.
The initial chapters of this report provide an orientation of 2012’s dealmaking and business activities.
Chapter 1 provides an overview of the trends in dealmaking during 2012 covering trends by deal type, stage of development, technology type and therapeutic indication.
Chapter 2 provides a review of the leading deals during 2012. Deals are listed by headline value, signed by bigpharma and bigbiotech, and most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 3 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of 2012 deals, as well as contract documents available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Chapter 4 provides a comprehensive directory of all partnering deals announced during 2012.
The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), therapy area and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report series also includes numerous tables and figures that illustrate the trends and activities in bigpharma partnering and dealmaking during 2012.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products during 2012.
**Please note that this product may take between 1-3 working days to deliver** SHOW LESS READ MORE >
Chapter 1 – Trends in dealmaking during 2012
1.1. Bigpharma dealmaking activity
1.2. Partnering by deal type
1.3. Partnering by industry sector
1.4. Partnering by stage of development
1.5. Partnering by technology type
1.6. Partnering by therapy area
Chapter 2 – Leading deals during 2012
2.2. Top deals by value during 2012
Chapter 3 – Bigpharma deals during 2012
3.2. How to use bigpharma partnering deals
3.3. Bigpharma partnering company profiles for 2012
Johnson & Johnson
Kyowa Hakko Kirin
Merck & Co
Chapter 4 – Partnering deals directory 2012
4.2. Company A-Z
4.3. By deal type
4.4. By stage of development
4.5. By technology type
4.6. By therapy area
About Wildwood Ventures
Recent titles from CurrentPartnering
Order Form – Reports
Table of figures
Figure 1: Bigpharma – top 50 – January to December 2012
Figure 2: Bigpharma deal frequency – 2012
Figure 3: Partnering by deal type during 2012
Figure 4: Partnering by industry sector during 2012
Figure 5: Partnering by stage of development during 2012
Figure 6: Partnering by technology type during 2012
Figure 7: Partnering by therapy area during 2012
Figure 8: Top deals by value during 2012